Intelligence Profile
Clinical Applications
Elamipretide (SS-31) is a mitochondria-targeted peptide being investigated for multiple conditions involving mitochondrial dysfunction. The compound has shown potential across several therapeutic areas, though clinical evidence remains limited to early-phase studies.
Primary Clinical Targets
Friedreich's Ataxia
The most advanced clinical application is in Friedreich's ataxia, a rare genetic disorder affecting mitochondrial function. A completed Phase 1/2 investigator-initiated study (NCT05168774) has been conducted, though results are not yet publicly available from the provided evidence.
Preclinical Applications Under Investigation
Recent research has explored elamipretide's potential in several conditions:
Neurological Conditions
- Stroke/Brain Injury: Studies suggest elamipretide may mitigate post-ischemic brain injury, potentially through modulation of inflammatory pathways when combined with other therapies
- Spinal Cord Injury: Research indicates the compound may promote recovery by preserving mitochondrial function and supporting neural remodeling
- Neurodegenerative Disease: Investigations show elamipretide may modulate α-synuclein aggregation and restore mitochondrial function, relevant to conditions like Parkinson's disease
- Age-related Cognitive Impairment: Studies suggest protective effects against neuroinflammation and cognitive decline in aging
Cardiovascular Applications
- Heart Failure with Preserved Ejection Fraction (HFpEF): Research demonstrates improved skeletal muscle performance in animal models through targeting mitochondrial dysfunction
Other Conditions
- Respiratory Disease: Studies explore anti-oxidant mechanisms for ozone-induced airway hyperresponsiveness
- Hepatic Injury: Research investigates protective effects in ischemia-reperfusion injury
- Athletic Performance: Safety and efficacy reviews examine potential applications for musculoskeletal injuries
Clinical Development Status
Evidence for elamipretide's clinical applications remains largely preclinical, with most findings from animal studies published in 2025-2026. While the completed Friedreich's ataxia trial represents the most advanced clinical evaluation, broader clinical validation across these various applications is still needed.
Disclaimer: This information is for educational purposes only and should not be considered personalized medical advice. Consult healthcare professionals for medical guidance.